Source Post
12/3/25 CAPR WATCH
Dec 3, 2025
The creator is highly skeptical of Capricorn Therapeutics' (CAPR) reported topline data for the hope three trial, alleging the company has changed its primary endpoint and is misrepresenting the results. He believes the reported changes are statistically insignificant and indicative of past "shenanigans" that led to approval failures.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.